This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Bamifylline is a methylxanthine derivative indicated in the treatment of bronchial asthma and other conditions with bronchospasm.
- Generic Name
- Bamifylline
- DrugBank Accession Number
- DB13203
- Background
Bamifylline is a selective A1 adenosine receptor antagonist.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Bamifylline (DB13203)
- Weight
- Average: 385.468
Monoisotopic: 385.211389749 - Chemical Formula
- C20H27N5O3
- Synonyms
- Bamifilina
- Bamifylline
- Bamifyllinum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Bronchial asthma •••••••••••• Treatment of Bronchospasm •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with Bamifylline. Abametapir The serum concentration of Bamifylline can be increased when it is combined with Abametapir. Abatacept The metabolism of Bamifylline can be increased when combined with Abatacept. Abiraterone The serum concentration of Bamifylline can be increased when it is combined with Abiraterone. Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Bamifylline. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Bamifylline hydrochloride 66466QLM3S 20684-06-4 PDBXHPORMXSXKO-UHFFFAOYSA-N
Categories
- ATC Codes
- R03DA08 — Bamifylline
- Drug Categories
- Alkaloids
- Analgesics
- Anti-Asthmatic Agents
- Autonomic Agents
- Bronchodilator Agents
- Cardiovascular Agents
- Central Nervous System Agents
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 Substrates
- Drugs for Obstructive Airway Diseases
- Heterocyclic Compounds, Fused-Ring
- Peripheral Nervous System Agents
- Purines
- Purinones
- Respiratory System Agents
- Sensory System Agents
- Vasodilating Agents
- Xanthine derivatives
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Imidazopyrimidines
- Sub Class
- Purines and purine derivatives
- Direct Parent
- Xanthines
- Alternative Parents
- 6-oxopurines / Alkaloids and derivatives / Pyrimidones / Benzene and substituted derivatives / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Lactams / 1,2-aminoalcohols / Ureas show 6 more
- Substituents
- 1,2-aminoalcohol / 6-oxopurine / Alcohol / Alkaloid or derivatives / Alkanolamine / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- ZTY15D026H
- CAS number
- 2016-63-9
- InChI Key
- VVUYEFBRTFASAH-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3
- IUPAC Name
- 8-benzyl-7-{2-[ethyl(2-hydroxyethyl)amino]ethyl}-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
- SMILES
- CCN(CCO)CCN1C(CC2=CC=CC=C2)=NC2=C1C(=O)N(C)C(=O)N2C
References
- General References
- AIFA Product Information: Bamifix (bamifylline hydrochloride) oral tablet [Link]
- External Links
- ChemSpider
- 15401
- 18752
- ChEBI
- 135605
- ChEMBL
- CHEMBL2110760
- ZINC
- ZINC000000608191
- Wikipedia
- Bamifylline
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Pill Oral 300 MG Suppository Rectal 250 MG Suppository Rectal 750 MG Tablet Oral 900 MG Tablet, coated Oral 600 MG Tablet, film coated Oral Pill Oral Suppository Rectal Tablet, coated Oral Tablet Oral Tablet, coated Oral 300 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.79 mg/mL ALOGPS logP 1.71 ALOGPS logP 1.1 Chemaxon logS -2.3 ALOGPS pKa (Strongest Acidic) 15.59 Chemaxon pKa (Strongest Basic) 8.7 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 81.91 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 108.05 m3·mol-1 Chemaxon Polarizability 42.04 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0009000000-f0b1eadc17ad43f52825 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0019000000-23ea2565cba7cbd41974 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-67834e6782bfd597a1bd Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00dm-3192000000-9b7b9966ec5e22a95eef Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0uxv-0039000000-18b75ec49008415c8b52 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-07vl-1092000000-d8898b611811eaeec314 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 184.79631 predictedDeepCCS 1.0 (2019) [M+H]+ 187.15431 predictedDeepCCS 1.0 (2019) [M+Na]+ 194.83778 predictedDeepCCS 1.0 (2019)
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- This enzyme listing is based on pharmacokinetic data for methylxanthines as a drug class. Methylxanthines are metabolized by CYP1A2. Bamifylline is a methylxanthine and is therefore assumed to be metabolized by this enzyme.
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB: PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95. doi: 10.1097/FPC.0b013e3283505d5e. [Article]
- Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ: Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics. 1996 Aug;6(4):291-6. [Article]
- Hakooz NM: Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab. 2009 May;10(4):329-38. [Article]
- Rasmussen BB, Brosen K: Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996 Jun;18(3):254-62. [Article]
- Theophylline metabolic pathway [Link]
- CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine [File]
Drug created at June 23, 2017 20:37 / Updated at June 05, 2021 09:12